PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33570057-0 2021 Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis. Sorafenib 105-114 nuclear receptor subfamily 1 group I member 2 Homo sapiens 166-169 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 57-66 nuclear receptor subfamily 1 group I member 2 Homo sapiens 4-23 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 57-66 nuclear receptor subfamily 1 group I member 2 Homo sapiens 25-28 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 57-66 nuclear receptor subfamily 1 group I member 2 Homo sapiens 212-215 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 146-155 nuclear receptor subfamily 1 group I member 2 Homo sapiens 4-23 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 146-155 nuclear receptor subfamily 1 group I member 2 Homo sapiens 25-28 33570057-1 2021 The pregnane X receptor (PXR) mediates the resistance of sorafenib in hepatocellular carcinoma (HCC) by promoting the clearance or elimination of sorafenib via the drug resistance-related downstream genes of the PXR. Sorafenib 146-155 nuclear receptor subfamily 1 group I member 2 Homo sapiens 212-215 33570057-4 2021 Here, we demonstrated that rhamnetin decelerated elimination of the molecular-targeting agent sorafenib in HCC cells via the microRNA (miR)-148a/PXR axis. Sorafenib 94-103 nuclear receptor subfamily 1 group I member 2 Homo sapiens 145-148 33570057-5 2021 Rhamnetin treatment decreased expression of the drug resistance-related downstream genes of PXR (cyp3a4 [cytochrome P-450] or mdr-1 [multi-drug resistance 1]), which mediate the metabolism or elimination of sorafenib in HCC cells. Sorafenib 207-216 nuclear receptor subfamily 1 group I member 2 Homo sapiens 92-95 30349375-10 2018 LINE-1 ORF-1p increased the transcription factor activity of PXR by interacting with PXR and enhancing its cytoplasmic/nuclear translocation, and recruiting PXR to its downstream gene promoter, in turn enhancing the expression of the sorafenib resistance-related genes, CYP3A4 and mdr-1. Sorafenib 234-243 nuclear receptor subfamily 1 group I member 2 Homo sapiens 61-64 30349375-10 2018 LINE-1 ORF-1p increased the transcription factor activity of PXR by interacting with PXR and enhancing its cytoplasmic/nuclear translocation, and recruiting PXR to its downstream gene promoter, in turn enhancing the expression of the sorafenib resistance-related genes, CYP3A4 and mdr-1. Sorafenib 234-243 nuclear receptor subfamily 1 group I member 2 Homo sapiens 85-88 30349375-10 2018 LINE-1 ORF-1p increased the transcription factor activity of PXR by interacting with PXR and enhancing its cytoplasmic/nuclear translocation, and recruiting PXR to its downstream gene promoter, in turn enhancing the expression of the sorafenib resistance-related genes, CYP3A4 and mdr-1. Sorafenib 234-243 nuclear receptor subfamily 1 group I member 2 Homo sapiens 85-88 30349375-12 2018 Conclusion: LINE-1 ORF-1p enhances the transcription factor activation of PXR and promotes the clearance of and resistance to sorafenib in HCC cells. Sorafenib 126-135 nuclear receptor subfamily 1 group I member 2 Homo sapiens 74-77 30114438-6 2018 The therapeutic studies show that ETS-1 promotes the Sorafenib-resistance of HCC tumor models and ETS-1 blockade enhances the anti-tumor capacity of Sorafenib by decreasing PXR activation. Sorafenib 149-158 nuclear receptor subfamily 1 group I member 2 Homo sapiens 173-176 29369785-0 2018 Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Sorafenib 29-38 nuclear receptor subfamily 1 group I member 2 Homo sapiens 0-19 29369785-5 2018 GST-pull down and LC-MS/MS was used to detect the interaction of PXR and Sorafenib. Sorafenib 73-82 nuclear receptor subfamily 1 group I member 2 Homo sapiens 65-68 29369785-8 2018 RESULTS: In the present work, we found high PXR level in clinical specimens is related to the poor prognosis of Sorafenib treated patients. Sorafenib 112-121 nuclear receptor subfamily 1 group I member 2 Homo sapiens 44-47 29369785-9 2018 By the mechanistic studies, we show that sorafenib binds to PXR and activates PXR pathway, and by which HCC cells develop sorafenib-resistance via activating. Sorafenib 41-50 nuclear receptor subfamily 1 group I member 2 Homo sapiens 60-63 29369785-9 2018 By the mechanistic studies, we show that sorafenib binds to PXR and activates PXR pathway, and by which HCC cells develop sorafenib-resistance via activating. Sorafenib 41-50 nuclear receptor subfamily 1 group I member 2 Homo sapiens 78-81 29369785-9 2018 By the mechanistic studies, we show that sorafenib binds to PXR and activates PXR pathway, and by which HCC cells develop sorafenib-resistance via activating. Sorafenib 122-131 nuclear receptor subfamily 1 group I member 2 Homo sapiens 60-63 29369785-10 2018 Moreover, PXR overexpression helps HCC cells to persist to sorafenib treatment. Sorafenib 59-68 nuclear receptor subfamily 1 group I member 2 Homo sapiens 10-13 29369785-12 2018 GENERAL SIGNIFICANCE: PXR mediates sorafenib-resistance in HCC cells and targeting PXR can be a useful approach to facilitate HCC treatment. Sorafenib 35-44 nuclear receptor subfamily 1 group I member 2 Homo sapiens 22-25 30271172-1 2018 Background: Pregnane X receptor (PXR), which is a member of the nuclear receptor protein family (nuclear receptor subfamily 1 group I member 2 [NR 1I2]), mediates the drug-resistance in the hepatocellular carcinoma (HCC) via enhancing the expression of drug-resistance-related genes which accelerate the clearance of antitumor drugs, eg, sorafenib. Sorafenib 338-347 nuclear receptor subfamily 1 group I member 2 Homo sapiens 12-31 30271172-1 2018 Background: Pregnane X receptor (PXR), which is a member of the nuclear receptor protein family (nuclear receptor subfamily 1 group I member 2 [NR 1I2]), mediates the drug-resistance in the hepatocellular carcinoma (HCC) via enhancing the expression of drug-resistance-related genes which accelerate the clearance of antitumor drugs, eg, sorafenib. Sorafenib 338-347 nuclear receptor subfamily 1 group I member 2 Homo sapiens 33-36 30271172-1 2018 Background: Pregnane X receptor (PXR), which is a member of the nuclear receptor protein family (nuclear receptor subfamily 1 group I member 2 [NR 1I2]), mediates the drug-resistance in the hepatocellular carcinoma (HCC) via enhancing the expression of drug-resistance-related genes which accelerate the clearance of antitumor drugs, eg, sorafenib. Sorafenib 338-347 nuclear receptor subfamily 1 group I member 2 Homo sapiens 97-142 30271172-1 2018 Background: Pregnane X receptor (PXR), which is a member of the nuclear receptor protein family (nuclear receptor subfamily 1 group I member 2 [NR 1I2]), mediates the drug-resistance in the hepatocellular carcinoma (HCC) via enhancing the expression of drug-resistance-related genes which accelerate the clearance of antitumor drugs, eg, sorafenib. Sorafenib 338-347 nuclear receptor subfamily 1 group I member 2 Homo sapiens 144-150 30271172-8 2018 The downregulation of PXR"s expression by miR-140-3p led to the reduction of PXR downstream genes" expression, which finally resulted in the decelerating clearance of sorafenib in HCC cells and enhanced the sensitivity of HCC cells to sorafenib. Sorafenib 167-176 nuclear receptor subfamily 1 group I member 2 Homo sapiens 22-25 30271172-8 2018 The downregulation of PXR"s expression by miR-140-3p led to the reduction of PXR downstream genes" expression, which finally resulted in the decelerating clearance of sorafenib in HCC cells and enhanced the sensitivity of HCC cells to sorafenib. Sorafenib 167-176 nuclear receptor subfamily 1 group I member 2 Homo sapiens 77-80 30271172-8 2018 The downregulation of PXR"s expression by miR-140-3p led to the reduction of PXR downstream genes" expression, which finally resulted in the decelerating clearance of sorafenib in HCC cells and enhanced the sensitivity of HCC cells to sorafenib. Sorafenib 235-244 nuclear receptor subfamily 1 group I member 2 Homo sapiens 22-25 30271172-8 2018 The downregulation of PXR"s expression by miR-140-3p led to the reduction of PXR downstream genes" expression, which finally resulted in the decelerating clearance of sorafenib in HCC cells and enhanced the sensitivity of HCC cells to sorafenib. Sorafenib 235-244 nuclear receptor subfamily 1 group I member 2 Homo sapiens 77-80 30271172-11 2018 Conclusion: Our study suggests that targeting PXR by miR-140-3p is a promising strategy for enhancing sorafenib"s efficacy during HCC treatment. Sorafenib 102-111 nuclear receptor subfamily 1 group I member 2 Homo sapiens 46-49 30114438-0 2018 ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR. Sorafenib 14-23 nuclear receptor subfamily 1 group I member 2 Homo sapiens 117-120